Nathalie Scholler

Summary

Affiliation: University of Pennsylvania
Country: USA

Publications

  1. pmc Validation of glypican-3-specific scFv isolated from paired display/secretory yeast display library
    Yonghai Li
    Medicine and Research Services, Philadelphia VA Medical Center, PA 19104, USA
    BMC Biotechnol 12:23. 2012
  2. doi Selection of antibody fragments by yeast display
    Nathalie Scholler
    Center for Research on Reproduction and Women s Health, Penn Ovarian Cancer Research Center, University of Pennsylvania School of Medicine, Philadelphia, PA, USA
    Methods Mol Biol 907:259-80. 2012
  3. pmc Use of yeast-secreted in vivo biotinylated recombinant antibodies (Biobodies) in bead-based ELISA
    Nathalie Scholler
    School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania 96104 6069, USA
    Clin Cancer Res 14:2647-55. 2008
  4. pmc CA125 in ovarian cancer
    Nathalie Scholler
    Center for Research on Early Detection and Cure of Ovarian Cancer School of Medicine, University of Pennsylvania Biomedical Research Building BRB II III, Suite 1355 421 Curie Blvd, PA 19104 6080, USA
    Biomark Med 1:513-23. 2007
  5. pmc Use of cancer-specific yeast-secreted in vivo biotinylated recombinant antibodies for serum biomarker discovery
    Nathalie Scholler
    Center for Research on Early Detection and Cure of Ovarian Cancer, School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania 19104, USA
    J Transl Med 6:41. 2008
  6. pmc Novel recombinant human b7-h4 antibodies overcome tumoral immune escape to potentiate T-cell antitumor responses
    Denarda Dangaj
    Department of Obstetrics and Gynecology, Ovarian Cancer Research Center, and Departments of Pathology and Laboratory Medicine and Hematology Oncology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA
    Cancer Res 73:4820-9. 2013
  7. pmc Redirected antitumor activity of primary human lymphocytes transduced with a fully human anti-mesothelin chimeric receptor
    Evripidis Lanitis
    Department of Obstetrics and Gynecology, Ovarian Cancer Research Center, University of Pennsylvania, Philadelphia, Pennsylvania 19104, USA
    Mol Ther 20:633-43. 2012
  8. pmc A universal strategy for adoptive immunotherapy of cancer through use of a novel T-cell antigen receptor
    Katarzyna Urbanska
    Department of Obstetrics and Gynecology, Ovarian Cancer Research Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania 19104, USA
    Cancer Res 72:1844-52. 2012
  9. pmc Tumor Regression and Delayed Onset Toxicity Following B7-H4 CAR T Cell Therapy
    Jenessa B Smith
    Department of Pathology and Laboratory Medicine, Center for Cellular Immunotherapies, Philadelphia, Pennsylvania, USA
    Mol Ther 24:1987-1999. 2016
  10. pmc Rapid isolation of high-affinity human antibodies against the tumor vascular marker Endosialin/TEM1, using a paired yeast-display/secretory scFv library platform
    Aizhi Zhao
    Penn Ovarian Cancer Research Center, Center for Research on Reproduction and Women s Health CRRWH, Department of Obstetrics and Gynecology, University of Pennsylvania, Philadelphia, PA 19104, USA
    J Immunol Methods 363:221-32. 2011

Collaborators

Detail Information

Publications15

  1. pmc Validation of glypican-3-specific scFv isolated from paired display/secretory yeast display library
    Yonghai Li
    Medicine and Research Services, Philadelphia VA Medical Center, PA 19104, USA
    BMC Biotechnol 12:23. 2012
    ..We hypothesized that we could utilize a recently described paired display/secretory yeast library to isolate human-derived scFv against glypican-3 for potential diagnostic and/or therapeutic application...
  2. doi Selection of antibody fragments by yeast display
    Nathalie Scholler
    Center for Research on Reproduction and Women s Health, Penn Ovarian Cancer Research Center, University of Pennsylvania School of Medicine, Philadelphia, PA, USA
    Methods Mol Biol 907:259-80. 2012
    ..This chapter gives an updated overview of the available systems of yeast display platforms and libraries, followed up by technical descriptions of selection methods of antibody fragments by yeast display...
  3. pmc Use of yeast-secreted in vivo biotinylated recombinant antibodies (Biobodies) in bead-based ELISA
    Nathalie Scholler
    School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania 96104 6069, USA
    Clin Cancer Res 14:2647-55. 2008
    ..Mouse monoclonal antibodies (mAb) and polyclonal antibodies (pAb) are commonly used, but because their production is lengthy and costly, recombinant antibodies are emerging as an attractive alternative...
  4. pmc CA125 in ovarian cancer
    Nathalie Scholler
    Center for Research on Early Detection and Cure of Ovarian Cancer School of Medicine, University of Pennsylvania Biomedical Research Building BRB II III, Suite 1355 421 Curie Blvd, PA 19104 6080, USA
    Biomark Med 1:513-23. 2007
    ..The specific location and functional proprieties of CA125 make it a therapeutic target of choice; clinical trials have demonstrated that anti-CA125 injections are well tolerated and suggest a potential survival benefit...
  5. pmc Use of cancer-specific yeast-secreted in vivo biotinylated recombinant antibodies for serum biomarker discovery
    Nathalie Scholler
    Center for Research on Early Detection and Cure of Ovarian Cancer, School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania 19104, USA
    J Transl Med 6:41. 2008
    ..We developed a novel technology that permits us to isolate recombinant antibodies directed against the potential serum biomarkers, to facilitate the further development of affinity reagents necessary to construct diagnostic tests...
  6. pmc Novel recombinant human b7-h4 antibodies overcome tumoral immune escape to potentiate T-cell antitumor responses
    Denarda Dangaj
    Department of Obstetrics and Gynecology, Ovarian Cancer Research Center, and Departments of Pathology and Laboratory Medicine and Hematology Oncology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA
    Cancer Res 73:4820-9. 2013
    ..We suggest that blocking of B7-H4/B7-H4 ligand interactions may represent a feasible therapeutic strategy for ovarian cancer...
  7. pmc Redirected antitumor activity of primary human lymphocytes transduced with a fully human anti-mesothelin chimeric receptor
    Evripidis Lanitis
    Department of Obstetrics and Gynecology, Ovarian Cancer Research Center, University of Pennsylvania, Philadelphia, Pennsylvania 19104, USA
    Mol Ther 20:633-43. 2012
    ....
  8. pmc A universal strategy for adoptive immunotherapy of cancer through use of a novel T-cell antigen receptor
    Katarzyna Urbanska
    Department of Obstetrics and Gynecology, Ovarian Cancer Research Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania 19104, USA
    Cancer Res 72:1844-52. 2012
    ....
  9. pmc Tumor Regression and Delayed Onset Toxicity Following B7-H4 CAR T Cell Therapy
    Jenessa B Smith
    Department of Pathology and Laboratory Medicine, Center for Cellular Immunotherapies, Philadelphia, Pennsylvania, USA
    Mol Ther 24:1987-1999. 2016
    ..This model system provides a unique opportunity for preclinical evaluation of safety approaches that limit CAR-mediated toxicity after tumor destruction in vivo...
  10. pmc Rapid isolation of high-affinity human antibodies against the tumor vascular marker Endosialin/TEM1, using a paired yeast-display/secretory scFv library platform
    Aizhi Zhao
    Penn Ovarian Cancer Research Center, Center for Research on Reproduction and Women s Health CRRWH, Department of Obstetrics and Gynecology, University of Pennsylvania, Philadelphia, PA 19104, USA
    J Immunol Methods 363:221-32. 2011
    ....
  11. pmc Mannose receptor (MR) engagement by mesothelin GPI anchor polarizes tumor-associated macrophages and is blocked by anti-MR human recombinant antibody
    Denarda Dangaj
    Department of Obstetrics and Gynecology, Penn Ovarian Cancer Research Center, University of Pennsylvania, Philadelphia, Pennsylvania, United States of America
    PLoS ONE 6:e28386. 2011
    ....
  12. pmc Genetic and pharmacologic inhibition of complement impairs endothelial cell function and ablates ovarian cancer neovascularization
    Selene Nunez-Cruz
    Penn Ovarian Cancer Research Center, Department of Obstetrics and Gynecology, University of Pennsylvania, Philadelphia, PA 19104, USA
    Neoplasia 14:994-1004. 2012
    ..Finally, the mouse VEGF(164) transcript was underexpressed in C3(KO) livers compare to C3(WT) livers. Thus, we conclude that complement inhibition blocks tumor outgrowth by altering EC function and VEGF(165) expression...
  13. pmc An orthotopic model of serous ovarian cancer in immunocompetent mice for in vivo tumor imaging and monitoring of tumor immune responses
    Selene Nunez-Cruz
    Penn Ovarian Cancer Research Center, Center for Research on Reproduction and Womans Health, Department of Obstetrics and Gynecology, University of Pennsylvania School of Medicine, USA
    J Vis Exp . 2010
    ..Non-tumor prone mice exhibit typical lifespan for C57Bl/6 mice and are fertile. These mice can be used as syngeneic allograft recipients for tumor cells isolated from Tg-MISIIR-TAg-DR26 mice...
  14. doi Immunocompetent mouse model of ovarian cancer for in vivo imaging
    Selene Nunez-Cruz
    Department of Obstetrics and Gynecology, Penn Ovarian Cancer Research Center, University of Pennsylvania, Philadelphia, PA, USA
    Methods Mol Biol 1049:425-33. 2013
    ..This animal model combines the advantages of syngeneic and transgenic mouse models as it permits to both monitor tumor growth by in vivo imaging and to analyze the tumor microenvironment of an immunocompetent host. ..
  15. pmc Novel surface targets and serum biomarkers from the ovarian cancer vasculature
    Dimitra Sasaroli
    Ovarian Cancer Research Center, University of Pennsylvania, Philadelphia, PA USA
    Cancer Biol Ther 12:169-80. 2011
    ..We have identified novel tumor-specific vasculature markers which appear promising for cancer serum diagnostics, molecular imaging and/or therapeutic targeting applications and warrant further clinical development...